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A multicenter cooperative study was conducted to clarify the prognosis of Japa-
nese patients with metastatic renal cell carcinoma in the era of molecular-targeted
therapy and the clinical usefulness of the Japanese metastatic renal cancer (JMRC)
prognostic classification. Of 389 consecutive patients for whom treatment was
started between 2008 and 2010 at 23 hospitals in Japan, 357 patients who received
vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)
or cytokine as initial systemic therapy were the subject of the present study.
Patients were classified into three prognostic groups according to the JMRC prog-
nostic classification. The endpoints were progression-free survival (PFS) and overall
survival (OS) after the start of the initial treatment. The median PFS and OS for the
entire cohort of 357 patients were 9.1 and 27.2 months, respectively. VEGFR-TKI
were selected for patients with multiple organ metastases, those with liver metas-
tasis, and those with bone metastasis. The median PFS and OS were 11.0 and
23.2 months and 5.4 and 38.2 months in the VEGFR-TKI group and the cytokines
group, respectively. The JMRC prognostic classification was useful as a prognostic
model for PFS and OS (c-indexes: 0.613 and 0.630 in patients who initially received
VEGFR-TKI and 0.647 and 0.642 in patients who received cytokines, respectively).
The present study showed for the first time the prognosis of Japanese patients
with metastatic renal cell carcinoma in the era of molecular-targeted therapy. The
JMRC prognostic classification may be clinically useful as a prognostic model.
T he introduction of molecule targeted therapy has markedlychanged the treatment of metastatic renal cell carcinoma
(RCC). According to the clinical guidelines, sunitinib, pazopa-
nib and temsirolimus have been used as the initial treatment
for RCC. Sorafenib, axitinib and everolimus have been admin-
istered to patients who do not respond to initial therapeutic
drugs.(1) The Memorial Sloan Kettering Cancer Center
(MSKCC) risk classification, which was established in the
cytokine era, is routinely used in the selection of these
drugs.(2) Several studies report that survival was longer than in
the cytokine era in Europe and the USA.(3) These molecule-
targeting drugs have also been commonly used in Japan since
2008. Therefore, the current prognosis of Japanese patients
may be better than that in the cytokine era.
However, cytokines including Interferon-alpha (IFN-a) and
Iterleukin-2 (IL-2), the use of which has markedly decreased
in Europe and the USA, are still used as the initial treatment
in Japan because two clinical studies involving a large number
of patients indicated that overall survival (OS) was markedly
longer in cytokine-treated patients than in the European and
American series.(4,5) However, marked differences were noted
in patient backgrounds and the social insurance systems.
Therefore, controversy surrounds whether the above result
should be accepted. Furthermore, progression-free survival
(PFS), which may be used as an index of the direct therapeutic
effects of drugs, has not yet been reported in Japanese patients
treated with cytokines because of the lack of useful drugs
other than cytokines and their continued administration to most
patients with progression.(4)
This multicenter cooperative study was conducted to clarify
the prognosis of Japanese patients with metastatic RCC in the
era of molecular-targeted therapy and PFS ⁄OS in patients trea-
ted with molecule-targeting drugs or cytokines as the initial
systemic treatment. We also used the MSKCC risk classifica-
tion and the Japanese metastatic renal cancer (JMRC) prognos-
tic classification(6) as models to predict PFS and OS after these
treatments in Japanese patients with metastatic RCC, and
examined their clinical usefulness.
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Patients and Methods
Patient population. Data on 389 consecutive patients for
whom treatment was started between 2008 and 2010 at 23
hospitals in Japan (Appendix) was analyzed. Of these, 357
patients who received vascular endothelial growth factor
receptor-tyrosine kinase inhibitor (VEGFR-TKI) or cytokine
as initial systemic therapy were the subject of the present
study. Patients who received mammalian target of rapamycin
(mTOR) inhibitor as first line systemic therapy were omitted
from this study because only one patient received temsiroli-
mus. Patients were included if they had a clinical and path-
ological diagnosis of RCC, clinical confirmation of the
presence of metastasis, no previous treatment of metastatic
lesions, and course observation for 3 months or longer,
except for early fatal cases. Exclusion criteria were as fol-
lows: the presence of other clinical cancers, insufficient clin-
ical data before and after the treatment, and withdrawal
from the study by the patient or his ⁄her family. The study
was performed after approval by the internal review boards
of the participating institutes.
Clinical, pathological and survival data were collected for
each patient. The performance status was assigned according
to the Eastern Cooperative Oncology Group Performance Sta-
tus scale. The stage was assigned according to the 2009 TNM
classification of the Union Internationale Contre le Cancer
(UICC).(7) Patients were classified into three prognostic groups
(favorable, intermediate and poor) according to the MSKCC
risk classification and JMRC prognostic classification.(2,6) The
pathological grade was determined according to the General
Rules for Clinical and Pathological Studies on Renal Cell Car-
cinoma in Japan. Tumor histology was classified into three
groups: clear cell carcinoma, clear cell carcinoma with sarco-
matoid features and non-clear cell carcinoma. Tumor responses
were determined by an investigator assessment according to
the Response Evaluation Criteria In Solid Tumors (RECIST)
criteria version 1.1.(8)
Statistical analysis. Patient characteristics are shown as a
median for continuous variables and the number of patients
with a percentage for categorical variables. The endpoints of
the present study were PFS and OS. PFS was calculated
from the date when systemic therapy was started to the date
of clinically-confirmed progression according to the RECIST
or was censored at the date of the last follow up, and med-
ian and 1-year PFS along with the 95% confidence intervals
(95% CI) were reported. OS was calculated from the date
when systemic therapy was started to the date of death as a
result of any cause or was censored at the date of the last
follow up, and median and 2-year OS along with the 95%
CI were reported. Survival distributions were estimated
using the Kaplan–Meier method, and PFS or OS was com-
pared among three prognostic groups according to the
MSKCC risk classification or JMRC prognostic classification
using the log-rank test. The prognostic classification for
PFS or OS, respectively, was measured by the overall con-
cordance index (c-index) for the survival analysis model.(9)
This index is defined as the proportion of usable patient
pairs in which the predictions and outcomes are concor-
dant.(10) The c-index obtained from the JMRC prognostic
classification was compared with that from the MSKCC risk
classification.
In all statistical analyses, P < 0.05 was regarded as signifi-
cant. All statistical analyses were performed using SAS version
9 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics. The distribution of baseline character-
istics for all 357 patients is presented in Table 1. A total of 30
(8%), 254 (71%) and 59 (17%) patients were classified into
the favorable, intermediate and poor risk groups, respectively,
according to the MSKCC risk classification; 14 patients (4%)
could not be classified. In contrast, 81 (23%), 140 (39%) and
129 (36%) patients were classified into the favorable, interme-
diate and poor prognostic groups, respectively, by the JMRC
prognostic classification; 7 patients (2%) could not be classi-
fied. At the time of analysis, 156 patients (44%) were still
alive, 190 patients (53%) had died of RCC and 11 patients
(3%) had died of other causes. The median follow up was
22 months (range: 1–66 months). The median PFS after the
start of systemic therapies was 9.1 months, and the 1-year PFS
rate was 42% (95% CI, 36–48%). Furthermore, the median OS
was 27.2 months, and the 2-year OS rate was 53% (95% CI,
48–59%).
Comparison of baseline patient characteristics between
patients who received vascular endothelial growth factor recep-
tor-tyrosine kinase inhibitor and those who received cyto-
kines. Of the patients evaluated in the present study, 233
patients received VEGFR-TKI: sunitinib (148), sorafenib (66),
axitinib (12) and pazopanib (7). A total of 124 patients were
treated with cytokines: IFN-a (116), IL-2 (3) and IFN-a+IL-2
(5). Gender, age and the incidence of metastasis at the initial
RCC diagnosis were similar between the two treatment groups;
however, patients who received cytokines had a higher rate of
prior nephrectomy and a lower rate of multiple organ metastases
than in patients who received VEGFR-TKI (Table 2). The rate





Median (range) 65 (17–87)


















Histology of 296 nephrectomized specimens
CCRCC only 241 81
CCRCC with sarcomatoid features 16 5
Non-CCRCC 33 11
Unknown 6 2
CCRCC, clear cell renal cell carcinoma; ECOG-PS, Eastern Cooperative
Oncology Group Performance Status.
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of lung metastasis was higher in the cytokine group, while those
of lymph node metastasis, bone metastasis and liver metastasis
were higher in the VEGFR-TKI group. The distribution of three
risk groups according to the MSKCC risk classification was sim-
ilar between the two treatment groups. However, the rate of
patients classified into the favorable prognostic group was higher
in patients who were treated with cytokines, while that of
patients classified into the poor prognostic group was higher in
patients who received VEGFR-TKI when the JMRC prognostic
classification was applied.
Progression-free survival in patients who initially received vas-
cular endothelial growth factor receptor-tyrosine kinase inhibi-
tors or cytokines. The median PFS after the start of systemic
VEGFR-TKI therapy for the cohort of 233 patients was
11.0 months. No significant differences were observed in the
median PFS among patients who received sunitinib, sorafenib,
axitinib or pazopanib (data not shown). Significant differences
were noted in the median PFS among the favorable (n = 16),
intermediate (n = 166) and poor (n = 44) risk groups, which
were stratified according to the MSKCC risk classification
(P = 0.003) (Fig. 1a). The c-index was 0.596 (95% CI: 0.558–
0.634) (Table 3). However, significant differences were also
observed in the median PFS among the three groups stratified
according to the JMRC prognostic classification (P = 0.013)
(Fig. 1b). The c-index was 0.613 (95% CI: 0.566–0.660),
which was not significantly different from that calculated using
the MSKCC risk classification (P = 0.493). The treatment was
discontinued in 202 out of the 233 patients who initially
received VEGFR-TKI due to progression (n = 134) or adverse
events (n = 68). Of these, secondary drugs were administered
to 128 (63%) (VEGFR-TKI: 63 patients, mTORI: 50, and oth-
ers: 15).
The median PFS after systemic cytokine therapy had been
started for the cohort of 124 patients was 5.4 months. No
significant differences were observed in the median PFS
among the three groups stratified according to the MSKCC risk
classification (P = 0.304) (Fig. 2a). The c-index was 0.564
(95% CI: 0.519–0.609). However, significant differences were
noted in the median PFS among the favorable (n = 40), inter-
mediate (n = 52) and poor (n = 27) prognostic groups, which
were stratified according to the JMRC prognostic classification
(P = 0.011) (Fig. 2b). The c-index was 0.647 (95% CI: 0.590–
0.705). A significant difference was observed in the c-index
between the two prognostic models (P = 0.005). The treatment
was discontinued in 113 out of the 124 patients who initially
received cytokines due to progression (n = 90) or adverse
events (n = 23). Of these, secondary drugs were administered
to 96 patients (85%) (VEGFR-TKI: 77 patients, and others:
19).
Overall survival in patients who initially received vascular
endothelial growth factor receptor-tyrosine kinase inhibitors or
cytokines. The median OS after the start of systemic
VEGFR-TKI therapy for the cohort of 233 patients was
23.2 months. Significant differences were noted in the med-
ian OS among the three groups stratified according to the
MSKCC risk classification (P < 0.001) (Fig. 3a, Table 4).
The c-index, the threshold of which was established as
3 years after the treatment, was 0.600 (95% CI: 0.562–
0.638). Significant differences were also observed in the
median OS among the three groups stratified according to
the JMRC prognostic classification (P < 0.001) (Fig. 3b).
The c-index was 0.630 (95% CI: 0.587–0.672), which was
not significantly different from that calculated using the
MSKCC risk classification (P = 0.178).
The median OS after the start of systemic cytokine ther-
apy for the cohort of 124 patients was 38.2 months. No sig-
nificant differences were observed in the median OS among
the three groups stratified according to the MSKCC risk
classification (P = 0.063) (Fig. 4a, Table 5). The c-index
was 0.584 (95% CI: 0.536–0.633). In contrast, significant
differences were noted in the median OS among the
three groups stratified according to the JMRC prognostic
classification (P = 0.001) (Fig. 4b). The c-index was 0.642
(95% CI: 0.578–0.706). No significant difference was
observed in the c-index between the two prognostic models
(P = 0.056).
Comparison of progression-free survival and overall survival
between patients who initially received vascular endothelial
growth factor receptor-tyrosine kinase inhibitors and those who
received cytokines in three prognostic groups according to the
Japanese metastatic renal cancer prognostic classification. Based
on the results described, we considered the JMRC prognostic
classification to be more useful than the MSKCC risk classifica-
tion as a prognostic model for PFS and OS. Therefore, we exam-
ined the therapeutic effects of VEGFR-TKI and cytokines in the
groups stratified according to this classification. As shown in
Table 5, no significant differences were observed in PFS or OS
between the two treatments in the favorable prognostic group. In
the intermediate and poor prognostic groups, the PFS tended to
be longer in patients treated with VEGFR-TKI than in those
Table 2. Baseline characteristics of patients who initially received









Male ⁄ female, % 76 ⁄ 24 76 ⁄ 24 0.973
Median (range) age, years 66 (17–85) 65 (34–87) 0.688




No. of metastatic sites
Single ⁄ multiple organ, % 36 ⁄ 64 55 ⁄ 45 <0.001
Sites of metastasis
Lung, % 58 81 <0.001
Lymph node, % 44 27 0.002
Bone, % 36 21 0.003
Liver, % 16 6 0.011
The date when initial
systemic therapy was started
2008, % 11 48
2009, % 33 24
2010, % 55 28 <0.001
MSKCC risk classification
Favorable, % 7 11
Intermediate, % 71 71
Poor, % 19 12 0.128
Unclassified, % 3 6
JMRC prognostic classification
Favorable, % 18 32
Intermediate, % 38 42
Poor, % 44 22 <0.001
Unclassified, % 1 4
JMRC, Japanese Metastatic Renal Cancer; MSKCC, Memorial Sloan-Ket-
tering Cancer Center; RCC, renal cell carcinoma; VEGFR-TKI, vascular
endothelial growth factor receptor-tyrosine kinase inhibitor.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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(a)
(b)
Fig. 1. Progression-free survival of 233 patients
who initially received vascular endothelial growth
factor receptor-tyrosine kinase inhibitor (VEGFR-
TKI) stratified by the Memorial Sloan Kettering
Cancer Center (MSKCC) risk classification (a) and
by the Japanese metastatic renal cancer (JMRC)
prognostic classification (b).
Table 3. Progression-free survival (PFS) in patients who were classified into three prognostic groups according to the MSKCC risk classification
or JMRC prognostic classification
Prognostic group Median, months HR (5% CI) c-index (95% CI) P-value†
VEGFR-TKIs group
MSKCC favorable (n = 16) 23.4 1 0.493
MSKCC intermediate (n = 166) 11.7 2.131 (1.031–4.408)
MSKCC poor (n = 44) 5.6 3.723 (1.658–8.359) 0.596 (0.558–0.634)
JMRC favorable (n = 41) 18.2 1
JMRC intermediate (n = 88) 12.7 1.427 (0.863–2.357)
JMRC poor (n = 102) 7.2 2.067 (1.253–3.409) 0.613 (0.56–0.660)
Cytokines group
MSKCC favorable (n = 14) 14.9 1 0.005
MSKCC intermediate (n = 88) 5.0 1.499 (0.786–2.857)
MSKCC poor (n = 16) <3.0 2.348 (0.913–6.039) 0.564 (0.519–0.609)
JMRC favorable (n = 40) 14.9 1
JMRC intermediate (n = 52) 4.8 1.830 (1.104–3.034)
JMRC poor (n = 27) 3.7 2.460 (1.313–4.609) 0.647 (0.590–0.705)
†Comparison between the c-index obtained from the JMRC prognostic classification and that from the MSKCC risk classification. CI, confidence
intervals; HR, Hazard ratio; JMRC, Japanese Metastatic Renal Cancer; MSKCC, Memorial Sloan-Kettering Cancer Center; VEGFR-TKI, vascular
endothelial growth factor receptor-tyrosine kinase inhibitor.
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treated with cytokines. However, no significant difference was
found in OS between the two treatments.
Discussion
The present study showed that the median OS was
27.2 months in Japanese patients with metastatic RCC in the
era of molecular-targeted therapy. VEGFR-TKI were selected
as the initial treatment for approximately two-thirds of the
patients, while cytokines were selected for one-third. Regard-
ing patient backgrounds, VEGFR-TKI were selected for
patients with multiple organ metastases, those who did not
undergo nephrectomy, those with liver metastasis, and those
with bone metastasis, in whom the prognosis was considered
to be relatively poor. The median PFS in VEGFR-TKI-treated
and cytokine-treated patients were 11.0 and 5.4 months,
respectively. As a prognostic model for PFS, the JMRC prog-
nostic classification was more useful than the MSKCC risk
classification in the cytokines group. However, no significant
difference was observed between the two prognostic models in
the VEGFR-TKI group. As a prognostic model for OS, no
significant difference was noted between the two models in
either group.
Previous clinical studies in Europe and the USA suggested
that the prognosis of patients with metastatic RCC was
improving with the introduction of molecular-targeted therapy.
Wahlgran et al.(3) reported that median survival was prolonged
to 7.5 months in patients with metastatic RCC for whom treat-
ment was started between 2000 and 2005 or between 2006 and
2008. However, the present study demonstrated that median
survival in Japanese patients with metastatic RCC after the
introduction of molecular-targeted therapy was 27.2 months.
As median survival was 21.4 months in the cytokine era,(4)
survival may also be prolonged in Japanese patients.
Although VEGFR-TKI, especially sunitinib, have been
administered to many Japanese patients and reported to be
clinically effective,(11) cytokines are still used as the initial
treatment because OS in Japanese patients with metastatic
RCC in the cytokine era has been found to be relatively pro-
longed.(4,6) The efficacy of cytokine therapy was previously
reported to be high in post-nephrectomy patients with lung
metastasis alone. In the present study, cytokines were also
(a)
(b)
Fig. 2. Progression-free survival of 124 patients
who initially received cytokines stratified by the
Memorial Sloan Kettering Cancer Center (MSKCC)
risk classification (a) and by the Japanese metastatic
renal cancer (JMRC) prognostic classification (b).
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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(a)
(b)
Fig. 3. Overall survival of 233 patients who
initially received vascular endothelial growth factor
receptor-tyrosine kinase inhibitor (VEGFR-TKI)
stratified by the Memorial Sloan Kettering Cancer
Center (MSKCC) risk classification (a) and by the
Japanese metastatic renal cancer (JMRC) prognostic
classification (b).
Table 4. Overall survival (OS) in patients who were classified into three prognostic groups according to the MSKCC risk classification or JMRC
prognostic classification
Prognostic group Median, months HR (95% CI) c-index (95% CI) P-value†
VEGFR-TKIs group
MSKCC favorable (n = 16) Not-reach 1 0.178
MSKCC intermediate (n = 166) 25.1 3.398 (1.248–9.254)
MSKCC poor (n = 44) 11.9 7.093 (2.500–20.127) 0.600 (0.562–0.638)
JMRC favorable (n = 41) Not-reach 1
JMRC intermediate (n = 88) 30.4 1.427 (0.863–2.357)
JMRC poor (n = 102) 13.6 2.067 (1253–3.409) 0.630 (0.587–0.672)
Cytokines group
MSKCC favorable (n = 14) 47.0 1 0.056
MSKCC intermediate (n = 88) 44.3 1.735 (0.969–3.109)
MSKCC poor (n = 16) 18.3 3.304 (1.887–5.785) 0.584 (0.536–0.633)
JMRC favorable (n = 40) 59.0 1
JMRC intermediate (n = 52) 27.9 2.572 (1.347–4.910)
JMRC poor (n = 27) 17.8 3.594 (1.745–7.404) 0.642 (0.578–0.706)
†Comparison between the c-index obtained from the JMRC prognostic classification and that from the MSKCC risk classification. CI, confidence
intervals; HR, Hazard ratio; JMRC, Japanese Metastatic Renal Cancer; MSKCC, Memorial Sloan-Kettering Cancer Center; VEGFR-TKI, vascular endo-
thelial growth factor receptor-tyrosine kinase inhibitor.
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administered to these patients. Although cytokine therapy, pri-
marily with IFN-a, has been considered to be effective, no
study has reported the PFS in Japanese patients with metastatic
RCC. This issue was clarified for the first time in the present
study, but the PFS was 5.4 months, which was similar to that
previously reported after the start of IFN-a therapy in Europe
and the USA.(12–14) Therefore, race-related differences might
not exist in the efficacy of cytokines.
In the present study, the median OS was 23.2 months in 233
patients who initially received VEGFR-TKI and 38.2 months in
124 who initially received cytokines. The PFS was 11 months in
the former and 5.4 months in the latter. A discrepancy was noted
between PFS and OS. Although this may be associated with var-
ious factors, they include a difference in the patient background.
Therefore, it may be necessary to stratify patients using a prog-
nostic model and examine PFS and OS. MSKCC(2) and mRCC
International Database Consortium (IDC) models are now rou-
tinely used as such prognostic models.(15) The MSKCC risk clas-
sification is a prognostic model established to stratify cytokine-
treated patients based on OS, but is also routinely used in
patients receiving molecule-targeting drugs. In many guide-
lines for the treatment of metastatic RCC, drugs are also
recommended based on this classification. A review in the cyto-
kine era indicated that there were marked differences in survival
and proportion of patients classified by MSKCC risk classifica-
tion between Japanese patients and patients in Europe and the
USA.(4,5) This was attributed to metastatic foci, which may influ-
ence the prognosis of patients,(16) not being evaluated in the
MSKCC risk classification. In contrast, in the JMRC prognostic
classification, a metastatic focus assessment (multiple metasta-
ses, bone metastasis alone and liver metastasis alone) was added
as a prognostic factor.(6) The c-index was 0.72 when OS was
evaluated through internal and external validations in Japanese
patients with metastatic RCC in the cytokine era. The questions
are whether the JMRC prognostic classification is applicable to
metastatic RCC patients in the era of molecular-targeted therapy,
and also which of the JMRC prognostic classification and
MSKCC risk classification is more useful.
In the present study, an evaluation of PFS in VEGFR-TKI-
treated patients revealed that they could be clearly stratified into
three prognostic groups using not only the JMRC model but also
the MSKCC model. Motzer et al.(17) report a nomogram as a
prognostic model for PFS in sunitinib-treated patients. The PFS
rate was calculated 12 months after the treatment using 11
(a)
(b)
Fig. 4. Overall survival of 124 patients who
initially received cytokines stratified by the
Memorial Sloan Kettering Cancer Center (MSKCC)
risk classification (a) and by the Japanese metastatic
renal cancer (JMRC) prognostic classification (b).
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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pretreatment factors including three parameters for the assess-
ment of metastatic foci, and the c-index was reported to be 0.633
when this nomogram was used. In contrast, the c-index was
0.613 when the JMRC prognostic classification, in which evalu-
ations were performed using only four parameters, was used,
and this was not markedly different from the c-index obtained
with the nomogram reported by Motzer et al.(2) Cytokine-treated
patients could be stratified into three groups with the JMRC
prognostic classification, but not with the MSKCC risk classifi-
cation. The c-index was 0.647 when the JMRC model was used,
and was significantly higher than that with the MSKCC model.
Karakiwiez et al.(18) report a nomogram, which was estimated
using five pretreatment factors, as a prognostic model for PFS in
treatment groups receiving cytokines.(18) The AUC, as a parame-
ter that replaced the c-index, was 70 to 75%, but it cannot be
used to compare the results of the PFS assessment between IFN-
a and VEGFR-TKI. However, the JMRC prognostic classifica-
tion facilitates the evaluation of PFS in patients treated with
VEGFR-TKI or cytokines, and may be clinically useful.
To predict OS, the results obtained were also similar to those
for PFS. Patients in both the VEGFR-TKI and cytokines groups
could be stratified into three groups using the JMRC prognostic
classification, and the c-indexes were 0.630 and 0.642, respec-
tively. Several models have been proposed as prognostic models
for OS.(15,19–22) Heng et al.(23) compared the IDC, Cleveland
Clinic Foundation (CCF), French, International Kidney Cancer
Working Group (IKCWG) and MSKCC models, and reported
that their c-indexes were 0.664, 0.662, 0.640, 0.668 and 0.657,
respectively; no marked differences were observed between
these models. The c-index of the JMRC model in the present
study was similar to these results. Further study to compare the
predictive ability on OS between the JMRC prognostic classifi-
cation and the IDC model, which is used in patients receiving
molecular-targeting drugs, would be warranted. Furthermore, we
might need to establish the new stratification model for Japanese
metastatic RCC patients because the c-index of the JMRC prog-
nostic classification was relative low.
We lastly examined PFS and OS of patients who initially
received VEGFR-TKI or cytokines in each risk group classi-
fied by the JMRC prognostic classification. No significant
differences were observed in OS between patients who
received VEGFR-TKI and those who received cytokines in
any prognostic group. This was attributed to the prolongation
of survival in the latter. The median OS in the favorable, inter-
mediate and poor prognostic groups were 59, 27.9 and
17.8 months, respectively. These values were 7 to 8 months
longer than the previously reported median OS in the cytokine
era.(6) The appearance of molecular-targeted therapy involving
VEGFR-TKI has facilitated the switch to effective drugs in the
early stage even in patients who initially received cytokines,
and this finding may be significant. A secondary treatment was
performed in 85% of patients in whom PD or AE required a
switch in the treatment administered. This may have contrib-
uted to the prolongation of OS despite a relatively short PFS
in cytokine-treated patients. Especially in the favorable prog-
nostic group stratified using the JMRC model, initial cytokine
therapy may be more advantageous from the perspectives of
survival and treatment costs.
A limitation of the present study was that it was a retrospec-
tive study. Various biases may have been added. In addition, it
was impossible to compare our model with the IDC model,
which is commonly used, due to problems regarding data col-
lection. As another limitation, there was no central review
because each investigator was responsible for evaluating
pathologies, images and treatment responses. However, we
clarified the prognosis of Japanese patients with metastatic
RCC in the era of molecular-targeted therapy, especially PFS
in patients who initially received cytokines, which is signifi-
cant. Although the results of the present study need to be veri-
fied, they indicated that the JMRC prognostic classification
may be useful as a prognostic model in Asian patients to
whom cytokines are frequently administered even in the era of
molecular-targeted therapy.
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